Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC

Jhanelle E. Gray; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki Hyeong Lee; Byoung Chul Cho; David Planchard; Luis Paz-Ares; Corinne Faivre-Finn; Johan F. Vansteenkiste; David R. Spigel; Catherine Wadsworth; Maria Taboada; Phillip A. Dennis; Mustafa Özgüroğlu; Scott J. Antonia

doi:10.1016/j.jtho.2019.10.002

Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC

Jhanelle E. Gray, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho, David Planchard, Luis Paz-Ares, Corinne Faivre-Finn, Johan F. Vansteenkiste, David R. Spigel, Catherine Wadsworth, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu, Scott J. Antonia

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.42-65; P

Original language	English
Pages (from-to)	288-293
Journal	Journal of Thoracic Oncology
Volume	15
Issue number	2
DOIs	https://doi.org/10.1016/j.jtho.2019.10.002
Publication status	Published - 1 Feb 2020

Keywords

Durvalumab
NSCLC
Overall survival
PACIFIC
Three-year update

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jtho.2019.10.002

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)
Faivre-Finn, C. (Corresponding participant)
Impact: Health and wellbeing

Cite this

Gray, J. E., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., Cho, B. C., Planchard, D., Paz-Ares, L., Faivre-Finn, C., Vansteenkiste, J. F., Spigel, D. R., Wadsworth, C., Taboada, M., Dennis, P. A., Özgüroğlu, M., & Antonia, S. J. (2020). Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC. Journal of Thoracic Oncology, 15(2), 288-293. https://doi.org/10.1016/j.jtho.2019.10.002

@article{d1399a654252476b81123e64df4730c6,

title = "Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC",

abstract = "BACKGROUND In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.42-65; P",

keywords = "Durvalumab, NSCLC, Overall survival, PACIFIC, Three-year update",

author = "Gray, {Jhanelle E.} and Augusto Villegas and Davey Daniel and David Vicente and Shuji Murakami and Rina Hui and Takayasu Kurata and Alberto Chiappori and Lee, {Ki Hyeong} and Cho, {Byoung Chul} and David Planchard and Luis Paz-Ares and Corinne Faivre-Finn and Vansteenkiste, {Johan F.} and Spigel, {David R.} and Catherine Wadsworth and Maria Taboada and Dennis, {Phillip A.} and Mustafa {\"O}zg{\"u}roğlu and Antonia, {Scott J.}",

year = "2020",

month = feb,

day = "1",

doi = "10.1016/j.jtho.2019.10.002",

language = "English",

volume = "15",

pages = "288--293",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier BV",

number = "2",

}

Gray, JE, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, R, Kurata, T, Chiappori, A, Lee, KH, Cho, BC, Planchard, D, Paz-Ares, L, Faivre-Finn, C, Vansteenkiste, JF, Spigel, DR, Wadsworth, C, Taboada, M, Dennis, PA, Özgüroğlu, M & Antonia, SJ 2020, 'Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC', Journal of Thoracic Oncology, vol. 15, no. 2, pp. 288-293. https://doi.org/10.1016/j.jtho.2019.10.002

TY - JOUR

T1 - Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC

AU - Gray, Jhanelle E.

AU - Villegas, Augusto

AU - Daniel, Davey

AU - Vicente, David

AU - Murakami, Shuji

AU - Hui, Rina

AU - Kurata, Takayasu

AU - Chiappori, Alberto

AU - Lee, Ki Hyeong

AU - Cho, Byoung Chul

AU - Planchard, David

AU - Paz-Ares, Luis

AU - Faivre-Finn, Corinne

AU - Vansteenkiste, Johan F.

AU - Spigel, David R.

AU - Wadsworth, Catherine

AU - Taboada, Maria

AU - Dennis, Phillip A.

AU - Özgüroğlu, Mustafa

AU - Antonia, Scott J.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - BACKGROUND In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.42-65; P

AB - BACKGROUND In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.42-65; P

KW - Durvalumab

KW - NSCLC

KW - Overall survival

KW - PACIFIC

KW - Three-year update

U2 - 10.1016/j.jtho.2019.10.002

DO - 10.1016/j.jtho.2019.10.002

M3 - Article

C2 - 31622733

SN - 1556-0864

VL - 15

SP - 288

EP - 293

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 2

ER -

Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Impacts

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)

Cite this